Related Experiment Video
Updated: Jul 18, 2025

Author Spotlight: Liujunzi Decoction as a Traditional Chinese Treatment for Coloproctitis Cancer
Published on: October 13, 2023
Monotropein inhibits colitis associated cancer through VDR/JAK1/STAT1 regulation of macrophage polarization
Yingyu Lu1, Yonger Chen1, Yuhua Li1
1School of Pharmaceutical Sciences, Guangzhou University of Chinese Medicine, Guangzhou, Guangdong 510006, PR China.
Abstract:
Colorectal cancer (CRC) is a growing concern due to its high morbidity and mortality, and the search for effective and less toxic active substances against inflammatory bowel diseases has been a hot topic in the research and development of drugs against CRC. It is reported that monotropein isolated from the roots of Morinda officinalis, can improve Dextran Sodium Sulfate (DSS)-induced ulcerative colitis in mice, but its therapeutic effects and mechanisms for CRC treatment are still to be investigated. In the present study, we first used molecular docking, BLI, CESTA, and DARTS methods to detest whether monotropein targets VDR proteins. In addition, we used tumor cell conditioned co-culture and four models of macrophage polarisation to investigate the regulation of four macrophage polarisations by monotropein using RT-PCR, IF and western blot. Furthermore, we further validated the target of action of monotropein for the treatment of Azoxymethane (AOM)/DSS induced colitis associated cancer (CAC) using knockout animals. Meanwhile, we further explored the mechanism of action of monotropein in regulating polarisation by detecting JAK/STAT1-related genes and proteins. Molecular docking and biofilm interference techniques showed that monotropein bound to the VDR, and additional results from CESTA and DARTS suggested that VDR proteins are targets of monotropein. Furthermore, in tumor cell conditioned co-cultures or LPS + IFN-γ induced RAW264.7 cells, VDR translocation to the nucleus was reduced, JAK1/STAT1 signaling pathway proteins were up-regulated, and macrophages were polarised towards the M1-type after monotropein intervention. Animal models in which normal VDR or myeloid VDR was knocked out confirmed that JAK1 levels in intestinal tissues were increased after monotropein intervention, macrophages were polarised towards the M1 type, and CAC paracarcinomas were ameliorated. Taken together, the present study concluded that monotropein inhibited colitis-associated cancers through macrophage polarisation regulated by VDR/JAK1/STAT1.
Insights
Monotropein, derived from Morinda officinalis, combats colitis-associated cancer by targeting the VDR/JAK1/STAT1 pathway. This natural compound promotes M1 macrophage polarization, reducing tumor progression and offering a less toxic therapeutic avenue for colorectal cancer (CRC).
Area of Science:
- Pharmacology and Molecular Biology
- Cancer Research
- Immunology
Background:
- Colorectal cancer (CRC) presents significant morbidity and mortality challenges.
- Investigating novel, less toxic therapeutic agents for CRC and inflammatory bowel diseases is crucial.
- Monotropein, from Morinda officinalis, shows potential but requires mechanism elucidation for CRC treatment.
Purpose of the Study:
- To determine if monotropein targets Vitamin D Receptor (VDR) proteins.
- To investigate monotropein's regulation of macrophage polarization.
- To elucidate the mechanism of monotropein in treating colitis-associated cancer (CAC).
Main Methods:
- Molecular docking, Bio-Layer Interferometry (BLI), Cellular Thermal Shift Assay (CESTA), and DNA endonuclease assay (DARTS) were used to identify VDR as a target.
- Co-culture systems and macrophage polarization models (RAW264.7 cells) analyzed using RT-PCR, immunofluorescence (IF), and Western blot.
- Azoxymethane (AOM)/DSS-induced CAC mouse models, including VDR knockout animals, were employed to validate therapeutic effects and signaling pathways (JAK/STAT1).
Main Results:
- Monotropein demonstrated binding to VDR, confirming it as a direct target.
- Monotropein intervention led to reduced VDR nuclear translocation, increased JAK1/STAT1 signaling, and M1 macrophage polarization.
- In vivo studies showed that monotropein ameliorated CAC in VDR-dependent manner, correlating with increased JAK1 levels and M1 polarization.
Conclusions:
- Monotropein effectively inhibits colitis-associated cancer.
- The mechanism involves VDR-mediated regulation of the JAK1/STAT1 signaling pathway, promoting M1 macrophage polarization.
- Monotropein represents a promising natural compound for CRC therapy, particularly in colitis-associated settings.
More Related Videos
07:44Studying the Effects of Tumor-Secreted Paracrine Ligands on Macrophage Activation using Co-Culture with Permeable Membrane Supports
Published on: November 28, 2019
09:01Non-invasive Assessment of the Efficacy of New Therapeutics for Intestinal Pathologies Using Serial Endoscopic Imaging of Live Mice
Published on: March 10, 2015
Related Concept Videos
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs that Destabilize Microtubules
Drugs that Stabilize Microtubules
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease I: Ulcerative Colitis
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...